Morgan Stanley raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $109 from $100 and keeps an Overweight rating on the shares ahead of “multiple catalysts” by year-end. The firm says the focus remains on hypothalamic obesity, which meaningfully expands the market opportunity and greater clarity on commercial readiness is expected next month, while the setmelanotide regulatory filing remains on track for 3Q25, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating
- Rhythm Pharmaceuticals reports Q2 EPS (75c), consensus (67c)
- Rhythm Pharmaceuticals announces anticipated upcoming milestones
- Rhythm Pharmaceuticals enrolls first patient in Part C of Phase 1 RM-718 trial
- Rhythm Pharmaceuticals sees FY25 non-GAAP operating expense $285M-$315M